Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $9

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $10 to $9.